Wockhardt gets FDA QIDP status for new pneumonia drug WCK 4873
This is the company’s third product to receive this QIDP status after WCK 771 and WCK 2349 last year further strengthening its new drug discovery program. QIDP status
Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform.
Under the deal, Eureka will apply its proprietary human sequence antibody libraries and its technology platform to discover antibodies recognizing intracellular proteins, which represent about 90% of cancer-specific
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Hutchinson’s Disease, Parkinson’s disease, Kuru, Creutzfeldt-Jakob disease and other spongiform encephalopathies remain major health problems. Currently there are very limited means
SignalRx was awarded a Phase 1 Small Business Technology Transfer Research (STTR) grant from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH),